SINOPHARM(01099) 智通财经· Zhi Tong Cai Jing·2024-03-24 22:26Core Insights - The company reported a revenue of 596.57 billion yuan for the year ending December 31, 2023, representing a year-on-year growth of 8.05% [1] - The net profit attributable to the parent company was 9.054 billion yuan, an increase of 6.19% year-on-year, with earnings per share at 2.9 yuan and a proposed final dividend of 0.87 yuan per share (tax included) [1] Revenue Breakdown - Revenue growth was primarily driven by increases in the pharmaceutical distribution, retail, and medical device distribution segments [1] - As of the end of 2023, the pharmaceutical distribution segment accounted for 71.44% of total revenue, up 0.19 percentage points year-on-year; the medical device distribution segment accounted for 21.09%, down 0.09 percentage points; and the retail segment remained stable at 5.78% [1] Profitability Metrics - The gross profit margin decreased by 0.46 percentage points year-on-year to 8.13% due to rapid growth in pharmaceutical distribution and regulatory-driven structural adjustments [1] - Despite the decline in gross margin, the company achieved a net profit of approximately 15.01 billion yuan, a year-on-year increase of 4.63%, with the net profit attributable to the parent company reaching approximately 9.054 billion yuan, up 6.19% [1]